VLS Valneva SE

VALNEVA Declaration of shares and voting rights: September 30, 2025

VALNEVA Declaration of shares and voting rights: September 30, 2025

VALNEVA

Declaration of shares and voting rights

September 30, 2025

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment B

Declaration date: October 6, 2025

Number of shares

composing the share capital of Valneva
Total number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal number of voting rights excluding suspended voting rights**
171,854,856 



ordinary shares with a par value of €0.15 each





187,978,646Transfer into bearer form of 653 shares with double voting rights









Double voting rights granted on 100 ordinary shares





Between September 1 & September 18, 2025









On September 29, 2025





187,854,324

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
06/10/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

 PRESS RELEASE

VALNEVA Declaration of shares and voting rights: September 30, 2025

VALNEVA Declaration of shares and voting rights: September 30, 2025 VALNEVA Declaration of shares and voting rights September 30, 2025__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: October 6, 2025 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal n...

 PRESS RELEASE

VALNEVA Déclaration d’actions et de droits de vote : 30 septembre 202...

VALNEVA Déclaration d’actions et de droits de vote : 30 septembre 2025 VALNEVA Déclaration d’actions et de droits de vote 30 septembre 2025__________________________________________________________________________________________ Dénomination sociale : VALNEVAAdresse du siège social : 6 rue Alain Bombard, 44800 Saint-HerblainMarché réglementé Euronext Paris - Compartiment B Date de la déclaration : 6 octobre 2025 Nombre d’actions composant le capital de ValnevaNombre total de droits de vote incluant les droits de vote suspendus*Origine de la variationDate à laquelle cette variation a ...

 PRESS RELEASE

Valneva Reports 95% Seroresponse Four Years After Single Shot of Chiku...

Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ® Long-lasting antibody persistence was comparable in older (65+) and younger adultsLong-term antibody persistence is a key competitive advantage for a vaccine targeting unpredictable outbreak diseases like chikungunya Saint-Herblain (France), September 30, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive antibody persistence data four years after vaccination with a single dose of its chikungunya vaccine IXCHIQ®. The results are in line with ...

 PRESS RELEASE

Valneva annonce un taux de séroréponse de 95% quatre ans après une vac...

Valneva annonce un taux de séroréponse de 95% quatre ans après une vaccination avec une seule dose du vaccin contre le chikungunya IXCHIQ® Persistance des anticorps chez les adultes âgés de 65 ans et plus, comparable à celle des jeunes adultesLa durabilité de la réponse immunitaire est un avantage compétitif clé pour un vaccin ciblant une maladie épidémique comme le chikungunya Saint-Herblain (France), le 30 septembre 2025 – (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui des données positives sur la persistance des anticorps quatre ans ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch